HEROIC (Heparin Requirement in Counterpulsation)

Phase 2

Terminated

Conditions: Cardiogenic Shock

Interventions: Other: Without Heparin
Drug: Heparin

Registration Number: NCT00445211

Lead Sponsor: William Beaumont Hospitals

Brief Summary: Patients with intra-aortic balloon pumps (catheters placed in the groin connected to a pump which assists the heart by opening and closing a balloon in the aorta, thereby decreasing the work of the heart and improving blood flow to the coronary arteries) often receive intravenous (IV) heparin (a "blood thinner") to prevent circulation problems in the leg (where they are inserted). When intra-aortic balloon pumps were initially developed, the catheters were larger than the catheters used today. Due to the large size of the catheter and the material used to make the catheter, it was thought that intravenous heparin would prevent poor blood flow to the leg that contained the temporary catheter. Intravenous heparin, however, has never been proven to maintain good blood flow in these patients. The catheters used with intra-aortic balloon pumps are now smaller in size and made of a material that is less likely to produce blood clots. It is not clear that heparin is needed with intra-aortic balloon pumps. Bleeding complications associated with intra-aortic balloon pumps may be decreased if heparin is not used. In 2004, 99 patients received intra-aortic balloon pumps in the cardiac catheterization labs at William Beaumont Hospital. These patients received intravenous heparin and experienced a large number of bleeding complications (27 patients required a blood transfusion). This study will help the investigators to clarify if heparin should or should not be routinely used in patients with intra-aortic balloon pumps.

Detailed Description: Potential patients will be identified in the cardiac catheterization lab when an intra-aortic balloon pump is placed. Patients who agree to participate in this study will be randomized (they will be selected to receive heparin or not to receive heparin with their intra-aortic balloon pump) by a process that is similar to flipping a coin. Patients will have a 50% chance of receiving heparin and a 50% chance of not receiving heparin. If a patient does not want to participate in the study, his/her cardiologist will decide if the patient will receive or not receive heparin. Intra-aortic balloon pumps have been used with and without intravenous heparin and there is no known increase in complications in patients who do not receive heparin. Risks include bleeding and possible blood clots/decreased blood flow to the leg with the catheter in both groups (due to different medical reasons). The patients in both groups will be monitored closely in the cardiac care unit while the intra-aortic balloon pump is in place to prevent and/or minimize complications.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 46

Inclusion Criteria

Age >/= 18 years
Able to provide consent
Insertion of Intra-aortic Balloon Pump (IABP) in William Beaumont Hospital (WBH) cath lab
Anticipated duration of IABP >/= 18 hours

Exclusion Criteria

Contraindications to heparin
Pre-existing condition requiring heparin administration (other than IABP)
IABP placed outside of the WBH cardiac catheterization lab prophylactically for high-risk percutaneous coronary intervention (PCI), without complications)
Pregnant women

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intra-Aortic balloon Pump without Heparin	Without Heparin	Intra-Aortic balloon Pump (IABP) without Heparin
Intra-Aortic balloon Pump with Heparin	Heparin	Intra-Aortic Balloon Pump (IABP) with Heparin

Primary Outcome Measures

Name	Time	Method
Major Ischemia (Decreased Blood Flow) During the Index Hospitalization	0-4 days post surgery	Count of participants with loss of Doppler signal or sensation or abnormal skin temperature, mottling or pallor in lower extremity requiring surgical intervention; or other major ischemic events including ischemic stroke; recurrent unstable ischemia (unstable angina, recurrent chest pain prompting definitive treatment such as re-percutaneous transluminal coronary angiography (PTCA), coronary artery bypass grafting (CABG), administration of thrombolytics); reinfarction including clinical symptoms or new ECG changes with creatine kinase (CK) elevation and positive creatine kinase-MB isoenzyme fraction; arterial thrombosis, embolus, dissection, or perforation; compartment syndrome; renal ischemia including new renal failure or need for dialysis; small bowel or splenic infarction; mesenteric or hepatic ischemia, or deep vein thrombosis.
Major Bleeding During the Index Hospitalization	0-4 days post surgery	Count of participants with hemorrhage associated with at least one of the following features as defined by the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria: Bleeding that results in a decrease in hemoglobin \>/= 5g.dL or a hematocrit decrease of \>/= 15% of baseline value; bleeding that is intracranial (confirmed by MRI or CT); bleeding that results in death.
Minor Ischemia (Decreased Blood Flow) During the Index Hospitalization	0-4 days post surgery	Count of participants with decreased arterial flow in lower extremity as presented by diminished pulse that resolves with balloon removal, and not resulting in any impairment of body function

Secondary Outcome Measures

Name	Time	Method
Hospital Death During the Index Hospitalization	0-4 post surgery
Intra-aortic Balloon Pump-related Death During the Index Hospitalization	0-4 days post surgery